Neuroblastoma

Updated: 2026-07-15

Overview

Neuroblastoma is an embryonal malignancy of the sympathetic nervous system that arises from neural crest cells. It typically presents in early childhood, with about 90% of cases diagnosed before age 5. The tumor can originate anywhere along the sympathetic chain but most commonly develops in the adrenal medulla. The disease exhibits remarkable clinical heterogeneity, ranging from spontaneous regression to aggressive metastatic spread. This variability stems from complex molecular and genetic factors that influence tumor behavior. Neuroblastoma accounts for approximately 8-10% of all childhood cancers and 15% of pediatric cancer deaths, making it a significant focus of pediatric oncology research.

Key Features

Neuroblastoma demonstrates several unique biological characteristics that distinguish it from other pediatric cancers. Tumor cells often secrete catecholamines, which can be detected in urine as elevated levels of homovanillic acid (HVA) and vanillylmandelic acid (VMA). The cancer's behavior is strongly influenced by molecular features including MYCN amplification, ALK mutations, and chromosomal alterations. About half of high-risk cases show MYCN oncogene amplification, which correlates with aggressive disease. Tumor histology, as classified by the International Neuroblastoma Pathology Committee, provides additional prognostic information.

Application Areas

In clinical practice, neuroblastoma management requires multidisciplinary collaboration across several specialties. Pediatric oncologists work closely with surgeons, radiologists, pathologists, and radiation oncologists to develop individualized treatment plans. Research applications focus on developing targeted therapies and immunotherapies. Notable advances include anti-GD2 immunotherapy (dinutuximab) and ALK inhibitors for ALK-mutated cases. The disease serves as a model for studying tumor evolution and cancer stem cells in pediatric malignancies.

Precautions

Early diagnosis significantly impacts outcomes, so healthcare providers should consider neuroblastoma in young children presenting with abdominal masses, bone pain, or unexplained systemic symptoms. Diagnostic workup should include imaging (CT/MRI), urine catecholamines, and bone marrow evaluation. Treatment precautions include careful monitoring for chemotherapy toxicity, particularly hearing loss from platinum agents. Long-term follow-up is essential to detect late effects including growth impairment, learning difficulties, and secondary malignancies. Genetic counseling should be offered for familial cases.

B2B Procurement Guide

Hospitals and research institutions procuring neuroblastoma treatments should prioritize FDA/EMA-approved therapies including dinutuximab, isotretinoin, and ALK inhibitors where indicated. Clinical trial participation is encouraged for high-risk cases. Diagnostic equipment procurement should include capabilities for MIBG scanning and molecular testing. Treatment centers should establish contracts with specialized pharmacies for compounding pediatric chemotherapy doses. Budget planning should account for supportive care medications and potential stem cell transplantation costs.